Characterizing outcomes of ERBB2-amplified biliary tract cancer.

被引：0
|
作者：
Fox, Daniel Aaron
Haro-Silerio, Jaime
Bhamidipati, Deepak
Meric-Bernstam, Funda
Pant, Shubham
Ross, Jeffrey S.
Hu, Zishuo Ian
Koay, Eugene Jon
Ludmir, Ethan B.
Cao, Hop Sanderson Tran
Tzeng, Ching-Wei D.
Chun, Yun Shin
Vauthey, Jean-Nicolas
Newhook, Timothy E.
Metwalli, Zeyad
Habibollahi, Peiman
Cox, Veronica L.
Kang, Hyunseon
Javle, Milind M.
Lee, Sunyoung S.
机构：
[1] Baylor Coll Med, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA
[5] Fdn Med Inc, Cambridge, MA USA
[6] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Radiat Oncol, Houston, TX USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Intervent Radiol, Houston, TX USA
[10] Univ Texas MD Anderson Canc Ctr, Dept Abdominal Imaging, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-3532-2370-7650-2700; 283-237-2581-144; 298-4768-3691-2722; 261-7540; 613-4678-146; 261-492-9019; 6; 3; 2; 291; 176; 1; 38092-22447; 38092-34303; 38092-18909; 38092-30467; 38092-19994; 38092-32474; 38092-25821; 38092-20248; 38092-20245; 38092-20212; 38092-27371; 38092-33627; 38092-30779; 38092-27507; 38114-38096-7094; 38092-24862; 38092-23140; 38092-22449; 38092-18438; 14; 5; 4;
D O I：
10.1200/JCO.2024.42.3_suppl.492
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：492 / 492
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
    Gomez, Henry L.
    Doval, Dinesh C.
    Chavez, Miguel A.
    Ang, Peter C. -S.
    Aziz, Zeba
    Nag, Shona
    Ng, Christina
    Franco, Sandra X.
    Chow, Louis W. C.
    Arbushites, Michael C.
    Casey, Michelle A.
    Berger, Mark S.
    Stein, Steven H.
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) : 2999 - 3005
  • [22] Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer.
    Gomez, H. L.
    Chavez, M. A.
    Doval, D. C.
    Nag, S.
    Chow, L. W.
    Chang, P. C.
    Ahmad, N. M.
    Berger, M.
    Arbushites, M.
    Westlund, R.
    Stanislaus, M.
    Zaks, T.
    Stein, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
  • [23] Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma
    Gottesdiener, Lee S.
    O'Connor, Shannon
    Busam, Klaus J.
    Won, Helen
    Solit, David B.
    Hyman, David M.
    Shoushtari, Alexander N.
    CLINICAL CANCER RESEARCH, 2018, 24 (23) : 5815 - 5819
  • [24] Influence of MRP4 levels on clinical outcomes in biliary tract cancer.
    Arroyo, Gerardo F.
    Sahores, Ana
    Ituarte, Ana Carolina
    Inklemona, Cristina
    Rojo, Sandra
    Kowalyszyn, Ruben Dario
    Davio, Carlos
    May, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 624 - 624
  • [25] Computational design of fusion proteins against ErbB2-amplified tumors inspired by ricin toxin
    Moghaddam, Yasser Ahmadi
    Maroufi, Asad
    Zareei, Sara
    Irani, Mehdi
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
  • [26] Impact of HER2-positivity on prognosis and targeted therapeutic outcomes in advanced biliary tract cancer.
    Lee, Choong-kun
    Seo, Dong Hyun
    Fox, Daniel Aaron
    Haro-Silerio, Jaime
    Chung, Taek
    Kim, Chang Gon
    Bhamidipati, Deepak
    Meric-Bernstam, Funda
    Pant, Shubham
    Javle, Milind M.
    Lee, Sunyoung S.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 629 - 629
  • [27] Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
    Yarlagadda, Bhavya
    Kamatham, Vaishnavi
    Ritter, Ashton
    Shahjehan, Faisal
    Kasi, Pashtoon M.
    NPJ PRECISION ONCOLOGY, 2019, 3 (1)
  • [28] Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
    Bhavya Yarlagadda
    Vaishnavi Kamatham
    Ashton Ritter
    Faisal Shahjehan
    Pashtoon M. Kasi
    npj Precision Oncology, 3
  • [29] Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies
    Shiu, K-K
    Wetterskog, D.
    Mackay, A.
    Natrajan, R.
    Lambros, M.
    Sims, D.
    Bajrami, I.
    Brough, R.
    Frankum, J.
    Sharpe, R.
    Marchio, C.
    Horlings, H.
    Reyal, F.
    van der Vijver, M.
    Turner, N.
    Reis-Filho, J. S.
    Lord, C. J.
    Ashworth, A.
    ONCOGENE, 2014, 33 (05) : 619 - 631
  • [30] Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies
    K-K Shiu
    D Wetterskog
    A Mackay
    R Natrajan
    M Lambros
    D Sims
    I Bajrami
    R Brough
    J Frankum
    R Sharpe
    C Marchio
    H Horlings
    F Reyal
    M van der Vijver
    N Turner
    J S Reis-Filho
    C J Lord
    A Ashworth
    Oncogene, 2014, 33 : 619 - 631
12345